Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
• 作者

  Topp Max S.; Duell Johannes; Zugmaier Gerhard; Attal Michel; Moreau Philippe; Langer Christian; Kroenke Jan; Facon Thierry; Einsele Hermann; Munzert Gerd;

  展开▼
• 作者单位

  Univ Hosp Wurzburg Wurzburg Germany;

  Univ Hosp Wurzburg Dept Internal Med 2 Wurzburg Germany;

  Amgen Res Munich GmbH Munich Germany;

  Univ Toulouse Toulouse France;

  Univ Hosp Hotel Dieu Nantes France;

  Kempten Clin Kempten Germany;

  Ulm Univ Ulm Germany;

  Reg Univ Hosp Lille Lille France;

  Univ Hosp Wurzburg Dept Internal Med 2 Wurzburg Germany;

  Boehringer Ingelheim GmbH &

  Co KG Ingelheim Germany;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词